Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr Alan Cohen joins MAP Pharmaceuticals

This article was originally published in Scrip

Executive Summary

Dr Alan Cohen has joined MAP Pharmaceuticals(US) as vice-president of clinical development and medical affairs, pulmonary. He will oversee development and execution of the company's paediatric asthma clinical programme, including Phase III trials for Unit Dose Budesonide. Dr Cohen has more than 20 years' therapeutic, clinical and medical experience and most recently served as chief medical officer and vice-president of global medical affairs, safety and pharmacovigilance at Jazz Pharmaceuticals.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC031091

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel